A Senate Judiciary Committee investigation reviewing over 50,000 pages of internal documents concluded that UnitedHealth Group deployed a series of aggressive strategies to increase Medicare Advantage risk scores and thereby boost federal payments. The probe found that the company organized in-home visits by nurses to capture additional diagnoses, offered financial incentives to physicians for documenting new conditions, and utilized artificial intelligence tools to mine electronic medical records for uncoded ailments—some of which lacked clinical confirmation. This practice, according to the report, inflated risk-adjusted reimbursements from the Centers for Medicare & Medicaid Services by an estimated 7% over three years. UnitedHealth Group has disputed any wrongdoing, asserting that its documentation and coding processes fully comply with Medicare regulations, and has pledged to cooperate with committee inquiries.

UnitedHealth Group released two Milliman‐commissioned actuarial studies estimating 2025 cost projections for Medicare Advantage versus traditional Medicare. The analysis found that federal payments to Medicare Advantage plans averaged $1,117 per member per month, compared with $1,234 under traditional Medicare—a savings of 9% or roughly $117 per person each month, totaling over $1,400 annually. The study attributed these savings to managed care efficiencies, provider networks, and value‐based arrangements. Additionally, the average non-dual eligible Medicare Advantage Prescription Drug beneficiary was projected to spend $3,651 on total healthcare costs in 2025, versus $7,790 under a standalone drug plan and Medigap G combination—a 53% reduction in out-of-pocket and premium expenses. Milliman estimated that these lower spending levels generated $63 billion in enhanced benefits and reduced cost-sharing for enrollees.

Following the release of the Senate report, UnitedHealth’s shares declined by approximately 2.5% in the subsequent trading session, reflecting investor concern over potential regulatory scrutiny and future repayment obligations. Analysts have raised questions about possible CMS audits of risk-adjustment submissions and the impact of any compliance penalties on 2024 earnings guidance. Conversely, the positive findings from the Milliman studies have prompted some strategists to reaffirm their long-term outlook on UnitedHealth’s Medicare Advantage business, citing its scale, data analytics capabilities, and the potential for continued margin expansion if managed care savings translate into supplemental benefit offerings that attract new membership.